The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.
The cell therapy segment, the pharmaceutical and biotechnology companies’ segment is going to dominate and grow faster during the forecast period from Type segment and End-Users segment respectively.
The risk of mutagenesis, high manufacturing cost of cell and gene therapy; are the challenges to the market.
Because of increasing prevalence of cancer and target disease, increase in the clinical trial of cell and gene therapy; provides enormous opportunities to the players in this market.
The escalation in the Asia Pacific market; is due to the steps taken by government to improve healthcare infrastructure, increasing research & development in pharmaceuticals, increase in outsourcing drug discoveries and research in life science.
North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.
The global Cell & Gene Therapy Manufacturing Services Market study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as; ABL, Inc. , Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec.
SPER Market Research study aims to provide market dynamics, demand and supply with yearly forecast to 2030. This report provides data for growth estimates and forecasts for Type segment- Cell Therapy (Allogeneic, Autologous, and Viral Vector), Gene Therapy (Non-viral Vector, Oligonucleotides, Viral Vector) for Application segment- Clinical Manufacturing, Commercial Manufacturing, for End-User segment- Academic & Research Institutes, Pharmaceutical & Biotechnology Companies.
This report also provides the data for key regional segments of North America, Europe, Asia-Pacific and Rest of the World.
This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.